View profile

FarmaKology Newsletter - Issue #38

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev


March 19 · Issue #38 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+3500 Subscribers ) !

Today's Startup
BellaSeno is a Medical Device Startup aiming to develop, manufacture and market a new generation of breast implants. Disrupting the currently prevailing paradigm of silicone implants which permanently introduce a foreign body into the patient, our highly porous implants are biodegradable by the body and augment the growth of natural tissue.Our technology platform leverages Additive Manufacturing (AM) which allows us to manufacture a range of products from cosmetic implants for filling of smaller defects, breast implants in a standardised size and shape as well as fully patient-specific implants based on a personalized medicine approach.
DM Bio said that it has made a contract development and manufacture organization (CDMO) agreement with GI Innovation concerning GI-301, an allergy treatment candidate, which is currently being developed by the latter.Under the accord, DM Bio will be responsible for developing the process for making drug substance for GI-301, improving its productivity, developing a system to examine its stability, and producing about 2,500 liters of samples for phase 2 clinical trial,GI Innovation plans to conduct clinical trials for GI-301 in Europe in September as a treatment for allergic diseases caused by immunoglobulin E (IgE), such as chronic idiopathic urticaria, atopic dermatitis, asthma, and food allergies.
An old malaria and autoimmune drug is showing promise as a potential treatment for COVID-19 – although health officials are urging caution until clinical trials are done.The drug, hydroxychloroquine, sold under the brand name Plaquenil, was reported March 9 in Clinical Infectious Diseases journal to be effective at killing the virus in laboratory experiments.
Elon Musk hasn’t said whether Tesla will comply with “shelter-in-place” steps taken in the San Francisco Bay Area to curb the spread of the coronavirus but he took to Twitter overnight to say his electric car company is willing to produce ventilators for hospitals that are running short of those critical medical devices. 
Italy is grappling with the coronavirus disease pandemic, which has ravaged the country since February. In just a month, the number of cases has reached more than 35,000. Over the past 24 hours, Italy has reported 475 additional deaths, increasing the death toll to a staggering 2,978, a few numbers away from Hubei Province’s toll, the epicenter of the pandemic where the virus originated.
Research & Study
Episode 102: Voices from the coronavirus pandemic, in Italy, New York, and the high seas by STAT | Free Listening on SoundCloud
Job Opportunities
COVID-19 | Corona Virus: Epidemiology, Pathophysiology, Diagnostics
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue